Loading data
ZYMENasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 105.97 m USD | 76.3 m USD | 76.01 m USD | 412.48 m USD | 26.68 m USD |
| Research and development expense | — | — | 143.62 m USD | 208.6 m USD | 199.75 m USD |
| Operating profit | -92.55 m USD | -137.11 m USD | -138.05 m USD | 130.53 m USD | -215.63 m USD |
| Profit before tax | -79.75 m USD | -116.61 m USD | -119.24 m USD | 135.23 m USD | -212.36 m USD |
| Income tax expense | 1.38 m USD | 6.08 m USD | -568 k USD | 10.89 m USD | -516 k USD |
| Net income (reported basis) | -81.13 m USD | -122.7 m USD | -118.67 m USD | 124.3 m USD | -211.84 m USD |
| Net income attributable to common shareholders | -81.13 m USD | -122.7 m USD | -118.67 m USD | 124.34 m USD | -211.84 m USD |
| Basic earnings per share | -1.08 USD/share | -1.62 USD/share | -1.72 USD/share | 1.91 USD/share | -4.11 USD/share |
| Diluted earnings per share | -1.08 USD/share | -1.62 USD/share | -1.72 USD/share | 1.9 USD/share | -4.61 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.